US Stocks

Stoke Therapeutics, Inc.

Stoke Therapeutics is a biopharmaceutical company that develops innovative medicines to treat severe genetic diseases. They use Targeted Augmentation of Nuclear Gene Output to formulate ASOs that upregulate protein expression. The company is conducting clinical trials on two candidates, STK-001 and STK-002, to treat Dravet syndrome and autosomal dominant optic atrophy, respectively.